ScholarIQanswers from OpenAlex
Premiere Research Institute
InstitutionResearch output, impact & collaborations
Premiere Research Institute is a institution indexed in ScholarIQ from OpenAlex.
What is known about Premiere Research Institute?
ScholarIQrecord summary
Premiere Research Institute is a research organisation in West Palm Beach, US. OpenAlex records 180 works and 32,950 citations for it.
How many works does Premiere Research Institute have?
ScholarIQindexed works
Premiere Research Institute has 180 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Premiere Research Institute have?
ScholarIQcitation count
Premiere Research Institute has 32,950 citations in the OpenAlex counts ScholarIQ stores.
What is the average h-index at Premiere Research Institute?
ScholarIQavg h-index
Premiere Research Institute has an average h-index of 40 in OpenAlex.
What is the ROR of Premiere Research Institute?
ScholarIQror
The ROR for Premiere Research Institute is on the source record.
What is the OpenAlex record for Premiere Research Institute?
ScholarIQopenalex
The OpenAlex for Premiere Research Institute is on the source record.
Who are the most-cited researchers behind Premiere Research Institute?
ScholarIQtop researchers by citations
What are the most-cited papers on Premiere Research Institute?
ScholarIQmost cited works
Donanemab in Early Symptomatic Alzheimer Disease
John R. Sims, Jennifer A. Zimmer, Cynthia Evans, Ming‐Chi Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Paul R. Solomon, Stephen Salloway, Liana G. Apostolova, Oskar Hansson, Craig Ritchie, Dawn A. Brooks, Mark A. Mintun, Daniel Skovronsky, TRAILBLAZER-ALZ 2 Investigators, Rafael Abreu, Pinky Agarwal, Puja Aggarwal, Marc Agronin, Alison Allen, Dario Altamirano, Gustavo Alva, James Andersen, Allan Anderson, Donald D. Anderson, Jennifer Arnold, Takashi Asada, Yasuhiro Aso, Vikram Atit, Ricardo Ayala, Michael Badruddoja, Hanna Badzio-jagiello, Michal Bajaček, Dávid Barton, David G. Bear, Sabrina Benjamin, Richard Bergeron, Perminder Bhatia, Sandra E. Black, Allan Block, Mohammad Reza Bolouri, Wendy Bond, Jean Bouthillier, Sharon A. Brangman, Bruce J. Brew, Sarah Brisbin, Toby Brisken, Amy Brodtmann, Mark Brody, Jared R. Brosch, Celia Brown, Paul Brownstone, Sylwia Bukowczan, Jeffrey M. Burns, A Cabrera, Horace Capote, Ángel Carrasco, José Yépez, Eric Chavez, Howard Chertkow, Urszula Chyrchel-Paszkiewicz, Anthony Ciabarra, Edward Clemmons, Daniel M. Cohen, Robert M. Cohen, Ian J. Cohen, Mauricio Concha, Brian Costell, Denis Crimmins, Yvette Cruz-pagan, Adolfo Cueli, Robert Cupelo, Maciej Czarnecki, David Darby, P. L. J. Dautzenberg, Peter Paul De Deyn, Jose De La Gandara, Kenneth Deck, David DiBenedetto, Mark DiBuono, Eric Dinnerstein, Ahmet Dirican, Shanker Dixit, Jacek Dobryniewski, Ryan Drake, Peter Drysdale, Ranjan Duara, John P. Duffy, Aaron Ellenbogen, Victor Faradji, Marc Feinberg, Robert Feldman, Simon Fishman, Stephen Flitman, Concetta Forchetti
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart J. Tepper, Messoud Ashina, Uwe Reuter, Jan Lewis Brandes, David Doležil, Stephen D. Silberstein, Paul Winner, Dean Leonardi, Daniel D. Mikol, Robert Lenz
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho, Michel D. Ferrari, David W. Dodick, Vince Galet, James Kost, Xiaoyin Fan, Heather Leibensperger, Samar Froman, Christopher Assaid, Christopher Lines, Hille Koppen, Paul Winner
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program
Sheena K. Aurora, Paul Winner, Marshall C. Freeman, Egilius L.H. Spierings, Jessica O. Heiring, Ronald E. DeGryse, Amanda M. VanDenburgh, Marissa E. Nolan, Catherine C. Turkel
A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents
Paul Winner, A. David Rothner, Joel R. Saper, Robert Nett, Mahnaz Asgharnejad, Antonio Laurenza, Randall Austin, Margaret Peykamian
How much of the research on Premiere Research Institute is open access?
ScholarIQopen access share
18%OPEN ACCESS